Phospho-ALK (Tyr1096) Antibody

What is the Phospho-ALK (Tyr1096) Antibody and what does it detect?

Phospho-ALK (Tyr1096) Antibody specifically recognizes the phosphorylated form of Anaplastic Lymphoma Kinase (ALK) at tyrosine residue 1096. This antibody is crucial for detecting activated ALK in both its full-length form (220 kDa) and in oncogenic fusion proteins such as NPM-ALK (80 kDa) . The phosphorylation at Tyr1096 represents an important activation marker and potential signaling node in ALK-mediated pathways, particularly relevant in oncogenic contexts .

What is the biological significance of ALK phosphorylation at Tyr1096?

Phosphorylation of ALK at Tyr1096 plays a significant role in ALK signaling. This site was identified through advanced phosphoproteomic analysis using techniques like PTMScan® and PhosphoScan® technologies . While some phosphorylation sites in ALK (like Tyr1604 in the activation loop) have well-established roles, Tyr1096 remains less characterized in full-length ALK receptors but has demonstrated importance in oncogenic fusion proteins like NPM-ALK . Research indicates that phosphorylation at this site is critical for NPM-ALK function in carcinoma cell lines and tumors, suggesting its importance in downstream signaling pathways that drive oncogenic transformation .

What are the main ALK fusion proteins where Tyr1096 phosphorylation is relevant?

The most extensively studied ALK fusion proteins where Tyr1096 phosphorylation has demonstrated relevance include:

• NPM-ALK: A 80 kDa protein resulting from the fusion of nucleophosmin (NPM) gene on chromosome 5 with the ALK gene on chromosome 2, prominent in anaplastic large cell lymphoma .

• EML4-ALK: A fusion protein created when the short amino-terminal region of the microtubule-associated protein EML4 fuses to the kinase domain of ALK, particularly important in non-small cell lung cancer (NSCLC) .

Phosphorylation at Tyr1096 has been shown to be functionally important specifically in NPM-ALK through multiple studies in carcinoma cell lines and tumor samples .

What are the optimal experimental conditions for using Phospho-ALK (Tyr1096) Antibody in Western blotting?

For optimal Western blotting results with Phospho-ALK (Tyr1096) Antibody:

The antibody demonstrates endogenous sensitivity, making it suitable for detecting native phosphorylated ALK proteins without requiring overexpression systems . Robust signal-to-noise ratios have been reported when using this antibody on various human cancer cell lines expressing ALK or its fusion variants.

How can researchers design phosphorylation-specific experiments to study ALK signaling using this antibody?

For comprehensive ALK phosphorylation studies:

• Experimental design should include positive controls (cells known to express phosphorylated ALK) and negative controls (ALK-negative cells or phosphatase-treated samples).

• Time-course experiments can be valuable, especially when studying ALK activation in response to growth factors or inhibitor treatment.

• Comparative analysis with other phospho-ALK antibodies (targeting different sites like Tyr1604) can provide insights into the sequential phosphorylation patterns during ALK activation .

• Complementary techniques recommended alongside Western blotting include:

  • Immunoprecipitation (using 1:50 dilution)

  • Mass spectrometry for comprehensive phosphoproteomic analysis

  • Functional assays connecting phosphorylation status to downstream signaling events

• For mechanistic studies, comparing wild-type ALK with Tyr1096 mutants (Y1096F) can elucidate the specific contribution of this phosphorylation site to ALK signaling and oncogenic transformation.

How should researchers address potential cross-reactivity issues with Phospho-ALK (Tyr1096) Antibody?

When interpreting results from Phospho-ALK (Tyr1096) Antibody experiments, researchers should consider:

• Specificity confirmation: The antibody is highly specific for human ALK phosphorylated at Tyr1096, but its reactivity should be confirmed in each experimental system. Species reactivity is primarily documented for human samples, though the antigen sequence may share homology with other species .

• Molecular weight verification: Correct identification of bands at expected molecular weights (220 kDa for full-length ALK and 80 kDa for NPM-ALK) is essential for confirming specificity .

• Phospho-specificity validation: Treatment with phosphatase should eliminate signal, confirming phospho-specificity of the antibody.

• Multi-antibody approach: Using both phospho-specific and total ALK antibodies in parallel provides a more complete picture of ALK expression and activation status.

• Negative controls: Include ALK-negative cell lines or tissues to confirm absence of non-specific binding.

What are the key considerations when interpreting conflicting phosphorylation data from different experimental approaches?

When facing contradictory results in ALK phosphorylation studies:

• Consider technical variables that may influence phosphorylation detection:

  • Sample preparation methods (lysis buffers, phosphatase inhibitors)

  • Cell culture conditions affecting baseline phosphorylation

  • Antibody lot-to-lot variations

• Evaluate the temporal dynamics of phosphorylation, as Tyr1096 may exhibit different phosphorylation kinetics compared to other sites like Tyr1078, Tyr1092, Tyr1131, Tyr1584, and Tyr1586 .

• Assess the relationship between phosphorylation at Tyr1096 and other phosphotyrosine sites, as hierarchical phosphorylation patterns may exist.

• Recognize that different experimental approaches (immunoblotting vs. mass spectrometry) have different sensitivities and specificities for detecting phosphorylation events .

• Consider that phosphorylation status may differ between full-length ALK and fusion proteins like NPM-ALK or EML4-ALK, potentially explaining discrepancies between studies focused on different ALK variants .

How can Phospho-ALK (Tyr1096) Antibody be utilized in studies of ALK inhibitor resistance mechanisms?

Investigating ALK inhibitor resistance using phospho-specific antibodies involves:

• Phosphorylation profiling: Monitor changes in Tyr1096 phosphorylation status before, during, and after development of resistance to ALK inhibitors in cellular and patient-derived models.

• Comparative analysis: Examine Tyr1096 phosphorylation alongside other phosphorylation sites to identify differential regulation in resistant cells.

• Signaling bypass mechanisms: Determine whether Tyr1096 phosphorylation persists despite inhibitor treatment, suggesting potential bypass mechanisms maintaining downstream signaling.

• Combinatorial approaches: Test combination treatments targeting both ALK and pathways potentially activated through Tyr1096-dependent signaling.

• Biomarker development: Evaluate whether Tyr1096 phosphorylation status correlates with response or resistance to ALK inhibitors in clinical samples, potentially serving as a predictive biomarker.

This site may be particularly relevant for resistance studies as phosphorylation at Tyr1096 has been shown to be important for NPM-ALK function in carcinoma cells and tumors .

What is the relationship between ALK Tyr1096 phosphorylation and other phosphorylation sites identified through phosphoproteomic studies?

Phosphoproteomic analyses have revealed multiple phosphorylation sites in ALK that become activated upon receptor stimulation:

• Activation pattern analysis: Quantitative phosphoproteomic studies have identified 11 phosphotyrosine sites in ALK that show significant increases upon activation, including Tyr1096 .

• Functional hierarchy: While Tyr1604 in the activation loop is well-characterized, Tyr1096 along with Tyr1078, Tyr1092, Tyr1131, Tyr1584, and Tyr1586 remain less characterized in full-length ALK context .

• Domain-specific phosphorylation: Tyr1507 lies within a consensus Shc-binding site (NPTpY) and plays a critical role in ALK-Shc interaction, whereas Tyr1096 may participate in different protein-protein interactions .

• Temporal dynamics: Different phosphorylation sites may exhibit variable kinetics of phosphorylation and dephosphorylation, potentially revealing sequential activation patterns.

• Therapeutic implications: Understanding the interdependence of these phosphorylation events could inform the development of more effective ALK inhibitors targeting specific phosphorylation-dependent functions.

Comprehensive phosphoproteomic studies have quantified 336 phosphorylation sites (207 phosphotyrosine, 78 phosphoserine, and 51 phosphothreonine) derived from 189 different proteins in ALK-activated versus control cells, providing a broader context for understanding ALK signaling networks .

What are the critical factors that influence detection sensitivity when using Phospho-ALK (Tyr1096) Antibody?

Several technical factors significantly impact detection sensitivity:

• Sample preservation: Phosphorylation status is highly labile; therefore, rapid sample processing with appropriate phosphatase inhibitors is essential for preserving Tyr1096 phosphorylation.

• Antibody quality and storage: Both monoclonal and polyclonal versions of Phospho-ALK (Tyr1096) antibodies are available, with specific storage recommendations (typically -20°C, avoiding freeze/thaw cycles) .

• Protein extraction method: The choice of lysis buffer can significantly affect phosphoprotein recovery; buffers containing strong detergents and phosphatase inhibitors typically yield better results.

• Signal amplification: For low-abundance samples, signal enhancement techniques such as enhanced chemiluminescence or tyramide signal amplification may improve detection.

• Blocking agents: For phospho-specific antibodies, bovine serum albumin (BSA) is often preferred over milk-based blocking agents, which can contain phosphatases that reduce signal.

The advertised sensitivity of the antibody is sufficient for detection of endogenous levels of Phospho-ALK (Tyr1096) , but optimization of these technical factors can significantly improve results in challenging samples.

How can researchers validate the specificity of phosphorylation signals in complex experimental systems?

Rigorous validation strategies include:

• Phosphatase treatment controls: Treating duplicate samples with lambda phosphatase should eliminate phospho-specific signals while leaving total protein signals intact.

• Genetic validation: Using ALK knockout models or CRISPR-edited cells with Tyr1096 mutations provides definitive confirmation of antibody specificity.

• Peptide competition: Pre-incubating the antibody with phosphorylated peptides containing the Tyr1096 sequence should block specific signals.

• Correlation with kinase activity: Pharmacological modulation of ALK activity using specific inhibitors should produce corresponding changes in Tyr1096 phosphorylation.

• Orthogonal detection methods: Confirming phosphorylation events using alternative techniques such as mass spectrometry provides independent verification of antibody-based results .

Both monoclonal and polyclonal antibodies against Phospho-ALK (Tyr1096) are available commercially, with the monoclonal version (such as D96H9) potentially offering higher specificity but potentially more limited epitope recognition compared to polyclonal alternatives .